Cochlear share price goes green as guidance strikes a chord

Commentary provided at today's annual general meeting appears to be music to the ears of shareholders.

| More on:
cochlear happy, share price rise, up, increase

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price is edging higher on Tuesday amid the company's annual general meeting.

In the first hour of trade, shares in the hearing implant device maker are up 0.4% to $256.13. Meanwhile, the broader S&P/ASX 200 Health Care Index (ASX: XHJ) is down slightly, dragged lower by Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH).

The Cochlear share price is now 34.6% above its 52-week low, enjoying a steady climb up and to the right over the past year, as shown below.

After suffering a temporary slump during the pandemic, Cochlear has come back stronger than ever in many respects. In its full-year results for FY23, the company posted record revenue, rebounded profitability, and a balance sheet without a trace of debt.

Today, Cochlear shareholders get to tune into the annual general meeting (AGM).

What's boosting the Cochlear share price today?

It's that time of the year when shareholders gather around to hear from management and vote on a range of items.

Often, the event can harbour insights into how the business is performing since releasing its latest financial figures. As such, an AGM can be a good pulse check for shareholders to put their minds at ease or to begin asking more questions.

Fortunately for Cochlear shareholders, the information tabled in today's AGM appears positive.

The full release is six pages long, encompassing an address by Cochlear chair Alison Deans and CEO Dig Howitt. However, much adulation is arguably built around the few details supplied on pages four and five.

Noted in Howitt's remarks, Cochlear's previous earnings guidance for FY24 of an increase in underlying net profit of between 16% and 23% still stands. Furthermore, the guidance does not factor in the company's recently cleared acquisition of Denmark-based Oticon Medical's cochlear implant business.

Given the heightened economic and geopolitical uncertainty, the reassurance is a positive for the Cochlear share price today.

Additionally, management expects "solid" market growth rates to enable high single-digit growth (i.e. 5% to 9%) in cochlear implant units during FY24.

Despite the growth in units, the company's market share gains are slated to stabilise from FY23. As it stands, Cochlear lays claim to more than 60% of the global market share in cochlear and acoustic implants.

Lastly, the target dividend payout policy of 70% underlying net profit is being maintained.

Based on the current Cochlear share price, the medical device company offers a dividend yield of approximately 1.3%.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »